↓ Skip to main content

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, October 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
22 Mendeley
Title
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Published in
Breast Cancer Research and Treatment, October 2011
DOI 10.1007/s10549-011-1799-1
Pubmed ID
Authors

Yunwei Han, Zhihao Yu, Shaoyan Wen, Bin Zhang, Xuchen Cao, Xin Wang

Abstract

Neutropenia is one of the most important dose-limiting toxicities and often the reason for dose reduction. In this study we aimed to assess whether chemotherapy-induced neutropenia could be a marker of efficacy and associate with increased survival. Data from a retrospective survey for early breast cancer patients in our hospital were reviewed. Three hundred and thirty-five patients who had been treated with six cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF) were studied. The association between chemotherapy-induced neutropenia and overall survival (OS) was assessed. According to a multivariate Cox model with time-varying covariates, hazard ratios of death were 0.434 (95% confidence interval (CI), 0.298-0.634; P < 0.001) for patients with mild neutropenia, and 0.640 (95% CI, 0.42-0.975; P = 0.038) for those with severe neutropenia. Neutropenia occurring in early breast cancer patients is an independent predictor of increased survival. These findings suggest that neutropenia in patients who receive chemotherapy is strongly associated with a better prognosis.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 5%
Unknown 21 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 23%
Unspecified 3 14%
Student > Master 3 14%
Researcher 3 14%
Professor 2 9%
Other 6 27%
Readers by discipline Count As %
Medicine and Dentistry 9 41%
Unspecified 4 18%
Biochemistry, Genetics and Molecular Biology 3 14%
Agricultural and Biological Sciences 2 9%
Immunology and Microbiology 2 9%
Other 2 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2011.
All research outputs
#1,783,013
of 7,419,766 outputs
Outputs from Breast Cancer Research and Treatment
#394
of 1,720 outputs
Outputs of similar age
#19,599
of 80,150 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#8
of 44 outputs
Altmetric has tracked 7,419,766 research outputs across all sources so far. This one has received more attention than most of these and is in the 62nd percentile.
So far Altmetric has tracked 1,720 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 80,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.